aprott/iStock via Getty Images
Hims & Hers Health (NYSE:HIMS) is down 7% in early morning trading after the U.S. FDA determined that there is no shortage of Eli Lilly’s (LLY) GLP-1 medication tirzepatide, the active ingredient in its weight loss and
Hims & Hers Health falls as FDA issues unfavorable compounded GLP-1 decision
